Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept efficacy and biomarkers in SLE
NCT05666336Phase 4Recruiting
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of telitacicept in systemic lupus erythematosus (SLE). Started Dec 2022; status: recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05666336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666336.